Tcrcure Nets Over $47M In Funding
02/16/22, 6:16 AM
Money raised
$47 million
Next-generation cancer immunotherapies developer TCRCure Biopharma has received over 300 million yuan ($47 million) in a new round of funding.
Company Info
Additional Info
With headcount spanning over150 professionals, TCRCure develops novel cancer immunotherapies that benefit patients who suffer from tumour progression, and chronic diseases, among others. TCRCure, which currently operates in Los Angeles, North Carolina, Chongqing and Guangzhou, claims to launch an initial public offering (IPO) in 2023.